MX2023012929A - Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. - Google Patents

Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.

Info

Publication number
MX2023012929A
MX2023012929A MX2023012929A MX2023012929A MX2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A
Authority
MX
Mexico
Prior art keywords
inhibitors
tyrosine kinase
shp2
combination therapies
egfr tyrosine
Prior art date
Application number
MX2023012929A
Other languages
English (en)
Spanish (es)
Inventor
Robert Goodenow
Mireille Gillings
Farbod Shojaei
Jill M Ricono
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of MX2023012929A publication Critical patent/MX2023012929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023012929A 2021-05-05 2022-05-04 Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. MX2023012929A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US202263320991P 2022-03-17 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2023012929A true MX2023012929A (es) 2023-11-13

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012929A MX2023012929A (es) 2021-05-05 2022-05-04 Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.

Country Status (8)

Country Link
US (1) US20220370456A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334317A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516998A (cg-RX-API-DMAC10.html)
AU (1) AU2022270106A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217092A1 (cg-RX-API-DMAC10.html)
IL (1) IL308225A (cg-RX-API-DMAC10.html)
MX (1) MX2023012929A (cg-RX-API-DMAC10.html)
WO (1) WO2022235815A1 (cg-RX-API-DMAC10.html)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO2015050345A1 (en) 2013-10-01 2015-04-09 Lg Electronics Inc. Control apparatus for mobile terminal and control method thereof
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
CN117263942A (zh) * 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药(苏州)有限公司 吡嗪类衍生物及其在抑制shp2中的应用
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
CA3217084A1 (en) * 2021-05-05 2022-11-10 Farbod Shojaei Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Also Published As

Publication number Publication date
AU2022270106A1 (en) 2023-12-14
US20220370456A1 (en) 2022-11-24
WO2022235815A1 (en) 2022-11-10
EP4334317A4 (en) 2025-03-05
CA3217092A1 (en) 2022-11-10
EP4334317A1 (en) 2024-03-13
IL308225A (en) 2024-01-01
JP2024516998A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
CL2020003330A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
CO2026004964A2 (es) Moduladores de kras
MY209419A (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
MX2021013317A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
CL2023002746A1 (es) Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas
MX2024000986A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
JOP20250150A1 (ar) علاجات السرطان باستخدام مثبطات prmt5 التعاونية مع mta
MX2024012445A (es) Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
BR112022018948A2 (pt) Métodos de tratamento de lesão pulmonar com inibidores de cgrp
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.